Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

Clinical Efficacy of Composite Autologous Chylated Fat and Concentrated Growth Factors for Treating Postinjection Alopecia After Facial Fillers: A Single-Center Retrospective Study

Tang S., Zhou G., Fu Q., Chen M.

Retrospective Study on Hair Loss, Hair Regeneration, published in J Cosmet Dermatol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
J Cosmet Dermatol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40501302
PMCID
PMC12159710
DOI
10.1111/jocd.70269
Citations
1

Abstract (original English)

Background Postinjection alopecia is a rare but significant complication of facial fillers, likely caused by compromised microcirculation and follicular damage. Effective treatments are needed, but regenerative therapies specifically for this etiology lack systematic investigation. Objective This study evaluated the efficacy and safety of combined autologous chylated fat (ACF) and concentrated growth factors (CGF) for treating acute alopecia following facial filler injection. Methods In this single-center, retrospective case series, nine female patients with acute alopecia (2-4 weeks post-HA filler) were treated between June 2021 and June 2024. Treatment involved three monthly subcutaneous injections of a 1:1 ACF and liquid CGF mixture (0.1 mL/cm 2 ). Outcomes were assessed at 6 months posttreatment initiation, including hair density, diameter, terminal/vellus ratio, anagen/telogen ratio, Global Aesthetic Improvement Scale (GAIS), and adverse events. Results All nine patients completed the 6-month follow-up. Significant improvements (p 2 , hair diameter from 52.3 ± 15.2 to 75.8 ± 21.7 μm, terminal/vellus ratio from 0.31 ± 0.11 to 1.27 ± 0.35, and anagen proportion from 18.4% ± 6.5% to 63.7% ± 14.9%. GAIS scores indicated high satisfaction. Treatment was well-tolerated, with only one patient reporting transient erythema. Conclusion Combined ACF and CGF represent a promising and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
FaceAdipose TissueHairHumansAlopeciaHyaluronic AcidIntercellular Signaling Peptides and ProteinsTreatment OutcomeCosmetic TechniquesInjections, Subcutaneous

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research